This is a preview of subscription content, log in via an institution to check access.
Reference
Goulart BHL, et al. Out-of-Pocket Costs for Tyrosine Kinase Inhibitors and Patient Outcomes in EGFR- and ALK-Positive Advanced Non-Small-Cell Lung Cancer. JCO Oncology Practice : OP2000692, 7 Dec 2020. Available from: URL: http://doi.org/10.1200/OP.20.00692
Rights and permissions
About this article
Cite this article
Financial burden associated with inferior survival in US patients with advanced NSCLC. PharmacoEcon Outcomes News 869, 15 (2021). https://doi.org/10.1007/s40274-021-7382-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7382-z